Clinical trial
Preventive Effectiveness of Primary Care Physician-led CGM-supported Comprehensive Intervention on Cardio-metabolic-immune Diseases in Community Patients With Type 2 Diabetes (Community Diabetes Control Project) -A Cluster Randomized, Open-label, Controlled Trial
NCT07885904 is registered in ClinicalTrials.gov with Xiangya Hospital of Central South University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Preventive Effectiveness of Primary Care Physician-led CGM-supported Comprehensive Intervention on Cardio-metabolic-immune Diseases in Community Patients With Type 2 Diabetes (Community Diabetes Control Project) -A Cluster Randomized, Open-label, Controlled Trial
- Lead sponsor
- Xiangya Hospital of Central South University
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- December 30, 2030
- Enrollment
- 15,400 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
type 2 diabetes mellitus
Arms
As registered; 2 arms.
-
intervention group
Medication, diet and exercise intervention
-
no intervention
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Percentage of Participants Achieving Glycated Hemoglobin (HbA1c) <7.0%
The percentage of participants with glycated hemoglobin (HbA1c) below 7.0% at 6 months after randomization. HbA1c will be measured using high-performance liquid chromatography in a laboratory certified under a national HbA1c standardization program and reported as a percentage (%).
-
Time to First Composite Cardio-Metabolic-Immune Clinical Outcome
Time in days from randomization to the first independently adjudicated event: cardiovascular death; nonfatal myocardial infarction; nonfatal ischemic or hemorrhagic stroke; heart failure hospitalization; end-stage kidney disease (long-term dialysis, kidney transplantation, or sustained eGFR \<15 mL/min/1.73 m2); hospitalization for diabetic foot ulcer/infection/gangrene or diabetes-related lower-limb amputation; sight-threatening diabetic retinopathy requiring retinal laser, intravitreal therapy, or surgery or new diabetes-related blindness; hospitalization for diabetic ketoacidosis or hyperosmolar hyperglycemic state; or new moderate-to-severe immune-mediated inflammatory disease (rheumatoid arthritis; psoriasis/psoriatic arthritis; Crohn disease/ulcerative colitis; systemic lupus erythematosus; or another disease prespecified in the endpoint charter). An independent blinded endpoint committee will adjudicate events from clinical records.
Lead sponsor's other trials
Xiangya Hospital of Central South University, most recent start first.
+169 more trials
Similar trials
Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.
+3,730 more trials See the condition page